Marine natural products and related compounds as anticancer agents: An overview of their clinical status

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 603-631

  Petit, Karina ^a   Biard, Jean François ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Brentuximab vedotin; Clinical trials; Cytarabine; Elisidepsin; Eribulin; ILX 651; KLH; Marine natural products; MMAE; MMAF; Plinabulin; Plitidepsin; PM00104; PM01183; PM060184; Salinosporamide A; Trabectedin; TZT 1027

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1, 3, 4 OCTADECANETRIOL; 1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; AE 941; BRENTUXIMAB VEDOTIN; BRYOSTATIN 1; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEHYDRODIDEMNIN B; DOLASTATIN 10; DOXORUBUCIN; ELISIDEPSIN; ERIBULIN; ERLOTINIB; GEMCITABINE; GLEMBATUMUMAB VEDOTIN; KEYHOLE LIMPET HEMOCYANIN; LURBINECTEDIN; PEMETREXED; PLINABULIN; SALINOSPORAMIDE A; SOBLIDOTIN; SQUALAMINE; TASIDOTIN; TRABECTEDIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACMUNE; VORINOSTAT; VORSETUZUMAB MAFODOTIN; ZALYPSIS;

BILIARY TRACT CANCER; BLADDER CANCER; BREAST CANCER; COLON CARCINOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOTHERAPY; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MARINE SPECIES; MELANOMA; MOLLUSC; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SPONGE (PORIFERA);

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASMS;

EID: 84876739313     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313040010     Document Type: Review

References (280)

1. Newman, D.J.; Cragg, G.M. Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010. J. Nat. Prod., 2012, 75, 311-335.
2. WHO. Fact Sheet N 297. http://www.who.int/mediacentre/factsheets/fs297/en/ (Accessed February 27, 2012).
3. Gerwick, W.H.; Moore, B.S. Lessons from the Past and Charting the Future of Marine Natural Products Drug Discovery and Chemical Biology. Chem. Biol, 2012, 19, 85-98.
4. Newman, D.J.; Cragg, G.M. Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials. J. Nat. Prod., 2004, 67, 1216-1238.
5. Mayer, A.M.S.; Glaser, K.B.; Cuevas, C; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci., 2010, 31(6), 255-265.
6. Vignesh, S; Raja, A.; James, R.A. Marine Drugs: Implications and Future Studies. Int. J. Pharmacol, 2011, 7(1), 22-30.
7. Glaser, K.B.; Mayer, A.M. A renaissance in marine pharmacology: from preclinical curiosity to clinical reality. Biochem. Pharmacol, 2009, 78(5), 440-448.
8. Erwin, P.M.; Lopez-Legentil, S.; Schuhmann, P.W. The pharmaceutical value of marine biodiversity for anti-cancer drug discovery. Ecol. Econ., 2010, 70, 445-451.
9. Banerjee, S.; Wang, Z.; Mohammad, M.; Sarkar, F.H.; Mohammad, R.M. Efficacy of Selected Natural Products as Therapeutic Agents against Cancer. J. Nat. Prod., 2008, 77(3), 492-496.
10. Bhatnagar, I.; Kim, S.K. Marine Antitumor Drugs: Status, Shortfalls and Strategies. Mar. Drugs, 2010, 8, 2702-2720.
11. Biard J.F. Les antitumoraux d'origine marine. Oceanis, 2001, 27(3-4), 449-497.
12. Cragg, G.M.; Newman, D.J.; Yang, S.S. Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J. Nat. Prod., 2006, 69, 488-498.
13. Kinghorn, A.D.; Chin, Y.W.; Swanson, S.M. Discovery of natural product anticancer agents from biodiverse organisms. Curr. Opin. Drug Disc, 2009, 7252, 189-196.
14. Kingston, D.G.I. Modern Natural Products Drug Discovery and Its Relevance to Biodiversity Conservation. J. Nat Prod., 2011, 74, 496-511.
15. Mayer, A.M.S.; Gustafson, K.R. Marine pharmacology in 2003-2004: Anti-tumor and cytotoxic compounds. Eur. J. Cancer, 2006, 42(14), 2241-2270.
16. Mayer, A.M.S.; Gustafson, K.R. Marine pharmacology in 2005-2006: Antitumor and cytotoxic compounds. Eur. J. Cancer, 2008, 44(16), 2357-2387.
17. Rawat, D.S.; Joshi, M.C.; Joshi, P.; Atheaya, H. Marine Peptides and Related Compounds in Clinical Trial. Anti-Cancer Agents-Med. Chem., 2006, 6, 33-40.
18. Simmons, T.L.; Andrianasolo, E.; McPhail, K.; Flatt, P.; Gerwick, W.H. Marine natural products as anticancer drugs. Mol. Cancer Ther., 2005, 4, 333-342.
19. Singh, R.; Sharma, M.; Joshi, P.; Rawat, D.S. Clinical Status of Anti-Cancer Agents Derived from Marine Sources. Anti-Cancer Agents-Med. Chem., 2008, 8, 603-617.
20. Cochrane library. http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html (Accessed February 27, 2012).
21. Clinical trials. http://clinicaltrials.gov/ct2/home (Accessed February 27, 2012).
22. WHO. http://apps.who.int/trialsearch/ (Accessed February 27, 2012).
23. Institut National du Cancer. http://www.e-cancer.fr/recherche/recherche-clinique/registre-des-essais-cliniques/registre-des-essais-cliniques (Accessed February 27, 2012).
24. European Union Clinical trials register. https://www.clinicaltrialsregister.eu (Accessed February 27, 2012).
25. IFPMA Clinical trials portal. http://clinicaltrials.ifpma.org/clinicaltrials/no_cache/fr/monportail/index.htm (Accessed February 27, 2012).
26. Canadian cancer trials. http://www.canadiancancertrials.ca/Default.aspx?lang=fr (Accessed February 27, 2012).
27. National Cancer Institute. http://www.cancer.gov/clinicaltrials (Accessed February 27, 2012).
28. Current controlled trials. http://www.controlled-trials.com/ (Accessed February 27, 2012).
29. The marine pharmaceutical pipeline. http://marinepharmacology.midwestern.edu/clinPipeline.htm (Accessed February 27, 2012).
30. Internet drug index. http://www.rxlist.com/(Accessed February 27, 2012).
31. Japanese clinical trials registry. http://www.umin.ac.jp/ctr/ (Accessed February 27, 2012).
32. Japan medical association center for clinical trials. http://www.jmacct.med.or.jp/english/ (Accessed February 27, 2012).
33. Aska Pharmaceutical. http://www.aska-pharma.co.jp/english/ (Accessed February 27, 2012).
34. Bedford laboratories. http://www.bedfordlabs.com/ (Accessed February 27, 2012).
35. Biosyn. http://www.biosyncorp.com/bc_downloads/vacmune.pdf (Accessed February 27, 2012).
36. Eisai Inc. http://www.eisai.com/ (Accessed February 27, 2012).
37. Enzon Pharmaceuticals. http://enzon.com/(Accessed February 27, 2012).
38. Genzyme Corporation. http://www.genzyme.com/ (Accessed February 27, 2012).
39. Nereus Pharmaceuticals. http://www.nereuspharm.com/ (Accessed February 27, 2012).
40. PharmaMar. http://www.pharmamar.com/ (Accessed February 27, 2012).
41. Seattle Genetics. http://www.seagen.com/(Accessed February 27, 2012).
42. Bergmann, W.; Feeney, R.J. Contributions to the study of marine products. XXXII. The nucleosides of sponges I. J. Org. Chem., 1951, 16(6), 981-987.
43. Field, H. J.; De Clercq, E. Antiviral Drugs - a short history of their discovery and development. Microbiology Today, 2004, 31, 58-61.
44. National Cancer Institute. Cancer Drug Information. http://www.cancer.gov/cancertopics/druginfo/cytarabine (Accessed April 11, 2012).
45. Miyawaki, S.; Ohtake, S.; Fujisawa, S.; Kiyoi, H.; Shinagawa, K.; Usui, N.; Sakura, T.; Miyamura, K.; Nakaseko, C.; Miyazaki, Y.; Fujieda, A.; Nagai, T.; Yamane, T.; Taniwaki, M.; Takahashi, M.; Yagasaki, F.; Kimura, Y.; Asou, N.; Sakamaki, H.; Handa, H.; Honda, S.; Ohnishi, K.; Naoe, T.; Ohno, R. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood, 2011, 117(82011), 2366-2372.
46. Xicoy, B.; Ribera, J.M.; Miralles, P.; La Cruz, J.; Oriol, A.; Valencia, E.; Morgades, M.; Mahillo, B.; de la Torre, J.; Tellez, M.J.; Brunet, S.; Esteve, J.; Hoelzer, D. Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. Med. Clin. (Barcelona), 2011, 136(8), 323-328.
47. Löwenberg, B.; Pabst, T.; Vellenga, E.; van Putten, W.; Schouten, H.C.; Graux, C.; Ferrant, A.; Sonneveld, P.; Biemond, B.J.; Gratwohl, A.; de Greef, G.E.; Verdonck, L.F.; Schaafsma, M.R.; Gregor, M.; Theobald, M.; Schanz, U.; Maertens, J.; Ossenkoppele, G.J. Cytarabine dose for acute myeloid leukemia. New Engl. J. Med., 2011, 364, 1027-1036.
48. Burnett, A.K.; Hills, R.K.; Milligan, D.; Kjeldsen, L.; Kell, J.; Russell, N.H.; Yin, J.A.; Hunter, A.; Goldstone, A.H.; Wheatley, K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol., 2011, 29(4), 369-377.
49. Thomas, X.G.; Dmoszynska, A.; Wierzbowska, A.; Kuliczkowski, K.; Mayer, J.; Shelekhova, T.; Gau, J.; Chou, W.; Buckstein, R.; Cermak, J.; Kuo, C.; Rocafiguera, A.O.; Koza, V.; Ravandi, F.; Kantarjian, H. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J. Clin. Oncol., 2011, 29(15), suppl-May 20, 6504.
50. Faderl, S.; Wetzler, M.; Rizzieri, D.; Schiller, G.J.; Jagasia, M.H.; Stuart, R.K.; Ganguly, S.; Avigan, D.; Craig, M.; Collins, R.; Maris, M.B.; Kovacsovics, T.; Goldberg, S.; Seiter, K.; Hari, P.; Ravandi, F.; Wang, E.S.; Eckert, S.; Huebner, D.; Kantarjian, H. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. J. Clin. Oncol., 2011, 29(15), suppl-May 20, 6503.
51. Harris, J.R.; Markl, J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron., 1999, 30(6), 597-623.
52. Stellar Biotechnologieds. Stellar KLH® Protein. http://stellarbiotechnologies.com/products/protein (Accessed April 11, 2012).http://stellarbiotechnologies.com/
53. Biosyn. Products and solutions. Keyhole Limpet Hemocyanin. http://www.biosyncorp.com/bc_seiten/bc_products.html (Accessed April 11, 2012).
54. Olsson, C.A.; Chute, R.; Rao, C.N. Immunologic reduction of bladder cancer recurrence rate. J. Urol., 1974, 111(2), 173-176.
55. Lamm, D.L. Laboratory and Clinical Experience with Keyhole limpet hemocyanin (Immucothel) in Superficial Bladder Cancer. Journal für Urologie und Urogynäkologie, 2003, 10(2), 18-21.
56. Lamm, D.L; DeHaven, J.I.; Riggs, D.R.; Delgra, C.; Burrell, R. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer. Urol. Res., 1993, 21(1), 33-37.
57. Echarti, C.; Jurincic-Winkler, C.D.; Klippel, K.F. Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma. Eur. Urol., 2000, 37 Suppl 3, 50-53.
58. Lamm, D.L; DeHaven, J.I.; Riggs, D.R. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol., 2000, 37 Suppl 3, 41-44.
59. Jurincic-Winkler, C.D.; von der Kammer, H.; Beuth, J.; Scheit, K.H.; Klippel, K.F. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma. Anticancer Res., 1996, 16(4A), 2105-2110.
60. Jurincic-Winkler, C.D.; Horlbeck, R.; von der Kammer, H.; Scheit, K.H.; Klippel, K.F. Adjuvant immunotherapy with keyhole limpet hemocyanin in category PT 2 N+ and PT 3-4, No-N+, Mo renal cell carcinoma. Wien Klin. Wochenschr., 1994, 106(14), 455-458.
61. Flamm, J.; Donner, G.; Bucher, A.; Höltl, W.; Albrecht, W.; Havelec, L. Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A., 1994, 33(2), 138-143.
62. Kleinknecht, S.; Bichler, K.H.; Strohmaier, W.L.; Postoperative long-term course of peripheral blood immune parameters and immunomodulating effects of keyhole limpet hemocyanin in patients with nonmetastatic renal cell carcinoma. Eur. Urol., 1992, 21(4), 315-322.
63. Flamm, J.; Bucher, A. Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder. Br. J. Urol., 1991, 67(1), 70-73.
64. Kalble, T.; Mohring, K.; Ikinger, U.; Riedasch, G.; Staehler, G. Intravesical prophylaxis of superficial bladder cancer with BCG and KLH-a prospective randomized trial. Urologe A., 1991, 30(2), 118-121.
65. Flamm, J.; Bucher, A.; Höltl, W.; Albrecht, W. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial. J. Urol., 1990, 144(2 Pt 1), 260-263.
66. Jurincic C.D., Engelmann U.; Gasch J.; Klippel K.F. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J. Urol., 1988, 139(4), 723-726.
67. Berd, D.; Maguire Jr., H.C.; Mastrangelo, M.J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res., 1984, 44(11), 5439-5443.
68. Freedman, A.; Neelapu, S.S.; Nichols, C.; Robertson, M.J.; Djulbegovic, B.; Winter, J.N.; Bender, J.F.; Gold, D.P.; Ghalie, R.G.; Stewart, M.E.; Esquibel, V.; Hamlin, P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol, 2009, 27(18), 3036-3043.
69. Koç, O.N.; Redfern, C; Wiernik, P.H.; Rosenfelt, F.; Winter, J.N.; Carter, W.D.; Gold, D.P.; Stewart, M.E.; Ghalie, R.G.; Bender, J.F. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J. Immunother., 2010, 33(2), 178-184.
70. Hsu, F.J.; Caspar, C.B.; Czerwinski, D.; Kwak, L.W.; Liles, T.M.; Syrengelas, A.; Taidi-Laskowski, B.; Levy, R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood, 1997, 89(9), 3129-3135.
71. Ibrahim, N.K.; Murray, J.L. Clinical development of the STn-KLH vaccine (Theratope). Clin. Breast Cancer, 2003, 3 (Suppl 4), S139-143.
72. Miles, D.W.; Towlson, K.E.; Graham, R.; Reddish, M.; Longenecker, B.M.; Taylor-Papadimitriou, J.; Rubens, R.D. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Brit. J. Cancer., 1996, 74(8), 1292-1296.
73. MacLean, G.D.; Reddish, M.A.; Koganty; R.R.; Longenecker, B.M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emphasis Tumor Immunol, 1996, 19(1), 59-68.
74. Chapman, P.B.; Morrissey, D.M.; Panageas, K.S.; Hamilton, W.B.; Zhan, C; Destro, A.N.; Williams, L.; Israel, R.J.; Livingston, P.O. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin. Cancer Res., 2000, 6(3), 874-879.
75. Chapman, P.B.; Morrisey, D.; Panageas, K.S.; Williams, L.; Lewis, J.J.; Israel, R.J.; Hamilton, W.B.; Livingston, P.O. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin. Cancer Res., 2000, 6(12), 4658-4662.
76. Kirkwood, J.M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon a-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/ C509801. J. Clin. Oncol, 2001, 19(9), 2370-2380.
77. Rinehart, K.L.; Holt, T.G.; Fregeau, N.L.; Stroh, J.G.; Keifer, P.A.; Sun, F.; Li, L.H.; Martin, D.G. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem., 1990, 55(15), 4512-4515 + erratum in: Rinehart, K.L. J. Org. Chem., 1991, 56(4), 1676.
78. Wright, A.E.; Forleo, D.A.; Gunawardana, G.P.; Gunasekera, S.P.; Koehn, F.E.; McConnell, O.J. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. J. Org. Chem., 1990, 55(15), 4508-4512.
79. Cuevas, C; Pérez, M.; Martín, M.J.; Chicharro, J.L.; Fernández-Rivas, C; Flores, M.; Francesch, A.; Gallego, P.; Zarzuelo, M.; de La Calle, F.; García, J.; Polanco, C; Rodríguez, I.; Manzanares, I. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org. Lett., 2000, 2(16), 2545-2548.
80. Pommier, Y.; Kohlhagen, G.; Bailly, C; Waring, M.; Mazumder, A.; Kohn, K.W. DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin-743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry, 1996, 35, 13303-13309.
81. Garcia-Rochal, M.; Garcia-Gravalos, M.D.; Avila, J. Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Brit. J. Cancer, 1996, 73, 875-883.
82. Izbicka, E.; Lawrence, R.; Raymond, E.; Eckhardt, G.; Faircloth, G.; Jimeno, J.; Clark, G.; von Hoff; D.D. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol, 1998, 9, 981-987.
83. European Medicines Agency. Human medicines. Yondelis. Assessment history. Yondelis-H-C-773-II-08: EPAR-Assessment Report-Variation. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/ 000773/WC500059175.pdf (Accessed April 11, 2012).
84. European Medicines Agency. Human medicines. Yondelis. Authorization details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000773/human_med_0 01165.jsp&jsenabled=true (Accessed April 11, 2012).
85. European Medicines Agency. Human medicines. Yondelis. Assessment history. Yondelis: EPAR-Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000773/WC500045836.pdf (Accessed April 11, 2012).
86. European Medicines Agency. Human medicines. Yondelis. EMEA/CHMP/608550/2009. http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500059271 (Accessed April 11, 2012).
87. Johnson-Johnson website. News. All news. FDA Issues Complete Response Letter for Trabectedin Combined With DOXIL. http://www.jnj.com/connect/news/all/20090910_130000 (Accessed April 11, 2012).
88. Pharmamar website. Products. Yondelis. http://www.pharmamar. com/yondelis.aspx (Accessed April 11, 2012).
89. Herzog, T.J.; Vermorken, J.B.; Pujade-Lauraine, E.; Li, J.; Bayever, E.; Gomez, J.; Yovine, A.; Monk, B.J. Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone. J. Clin. Oncol., 2009, 27(15s), 5550.
90. Krasner, C.N.; Poveda, A.; Herzog, T.; Vermorken, J.; Monk, B.; Zintl, P.; Li, J.; Su, Y.; Dhawan, R.; Kaye, S. Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin with pegylated doxorubicin (PLD) versus PLD alone. J. Clin. Oncol., 2009, 27(15s), 5526.
91. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann. Oncol., 2009, 20(11), 1794-802.
92. Poveda, A.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: results from a PPS cohort of a phase III study. J. Clin. Oncol., 2010, 28(7s), 5012.
93. Kong, B.; Biakhov, M.; Kelley, J.L.; Nunez, J.; Lebedinsky, C.; Parekh, T.V.; Vermorken, J.B. Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone. J. Clin. Oncol., 2010, 28(7s), e15529.
94. Monk, B.J.; Herzog, T.J.; Kaye, S.B.; Krasner, C.N.; Vermorken, J.B.; Muggia, F.M.; Pujade-Lauraine, E.; Lisyanskaya, A.S.; Makhson, A.N.; Rolski, J.; Gorbounova, V.A.; Ghatage, P.; Bidzinski, M.; Shen, K.; Ngan, H.Y.; Vergote, I.B.; Nam, J.H.; Park, Y.C.; Lebedinsky, C.A.; Poveda, A.M. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J. Clin. Oncol., 2010, 28(19), 3107-3114.
95. Del Campo, J.M.; Muñoz-Couselo, E.; Diaz de Corcuera, I.; Oaknin, A.T.; Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer. Expert Rev. Anticancer Ther., 2010, 10(6), 795-805.
96. Colombo, N. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study. Int. J. Gynecol. Cancer, 2011, 21(10 Suppl 1), S12-6.
97. Kaye, S.B.; Colombo, N.; Monk, B.J.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-Cisarz, E.; Hagberg, H.; Vergote, I.; Lebedinsky, C.; Parekh, T.; Santabárbara, P.; Park, Y.C.; Nieto, A.; Poveda, A. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann. Oncol, 2011, 22(1), 49-58.
98. Poveda, A.; Vergote, I.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-Cisarz, E.; Hagberg, H.; Kaye, S.B.; Colombo, N.; Lebedinsky, C; Parekh, T.; Gómez, J.; Park, Y.C.; Alfaro, V.; Monk, B.J. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann. Oncol, 2011, 22(1), 39-48.
99. Sehouli, J.; Alfaro, V.; González-Martín, A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Ann. Oncol, 2012, 23(3), 556-562.
100. Monk, B.J.; Sill, M.W.; Hanjani, P.; Edwards, R.; Rotmensch, J.; De Geest, K.; Bonebrake, A.J.; Walker, J.L. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol, 2011, 120(3), 459-463.
101. Cioffi, A.; Italiano, A. Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma. Expert Opin. Drug Metab. Toxicol, 2012, 8(1), 113-122.
102. Simpson, E.L.; Rafia, R.; Stevenson, M.D.; Papaioannou, D. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Health Technol. Assess., 2010, 14(Suppl 1), 63-67.
103. Schmitt, T.; Keller, E.; Dietrich, S.; Wuchter, P.; Ho, A.D.; Egerer, G. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis. Mar. Drugs., 2010, 8(10), 2647-2658.
104. Soini, E.J.; García San Andrés, B.; Joensuu, T. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann. Oncol, 2011, 22(1), 215-223.
105. Thornton, K.A Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Core Evid., 2010, 15(4),191-198.
106. Gronchi, A.; Bui, B.N.; Bonvalot, S.; Pilotti, S.; Ferrari, S.; Hohenberger, P.; Hohl, R.J.; Demetri, G.D.; Le Cesne, A.; Lardelli, P.; Pérez, I.; Nieto, A.; Tercero, J.C.; Alfaro, V.; Tamborini, E.; Blay, J.Y. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann. Oncol, 2012, 23(3), 771-776.
107. Paz-Ares, L.; López-Pousa, A.; Poveda, A.; Balafla, C; Ciruelos, E.; Bellmunt, J.; Del Muro, J.G.; Provencio, M.; Casado, A.; Rivera-Herrero, F.; Izquierdo, M.A.; Nieto, A.; Tanovic, A.; Cortes-Funes, H.; Buesa, J.M. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest. New Drugs, 2012, 30(2), 729-740.
108. Baruchel, S.; Pappo, A.; Krailo, M.; Baker, K.S.; Wu, B.; Villaluna, D.; Lee-Scott, M.; Adamson, P.C.; Blaney, S.M. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group. Eur. J. Cancer, 2012, 48(4), 579-585.
109. Sanfilippo, R.; Grosso, F.; Jones, R.L.; Banerjee, S.; Pilotti, S.; DTncalci, M.; Tos, A.P.; Raspagliesi, F.; Judson, I.; Casali, P.G. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol. Oncol, 2011, 123(3), 553-556.
110. Monk, B.J.; Blessing, J.A.; Street, D.G.; Muller, C.Y.; Burke, J.J.; Hensley, M.L. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study. Gynecol. Oncol, 2012, 124(1), 48-52.
111. Fayette, J.; Boyle, H.; Chabaud, S.; Favier, B.; Engel, C; Cassier, P.; Thiesse, P.; Méeus, P.; Sunyach, M.P.; Vaz, G.; Ray-Coquard, I.; Ranchère, D.; Decouvelaere, A.V.; Alberti, L.; Pérol, D.; Blay, J.Y. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs, 2010, 21(1), 113-119.
112. Demetri, G.D.; Chawla, S.P.; von Mehren, M.; Ritch, P.; Baker, L.H.; Blay, J.Y.; Hande, K.R.; Keohan, M.L.; Samuels, B.L.; Schuetze, S., Lebedinsky, C; Elsayed, Y.A.; Izquierdo, M.A.; Gómez, J.; Park, Y.C.; Le Cesne, A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J. Clin. Oncol., 2009, 27(25), 4188-4196.
113. Demetri, G.D.; Schuetze, S.; Blay, J.; Chawla, S.; von Mehren, M.; Casali, P.; Morris, D.; Bayever, E.; Alfaro, V.; LeCesne, A. Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide. J. Clin. Oncol., 2009, 27(15S), 538.
114. Tedesco, K.L.; Blum, J.L.; Goncalves, A.; Lubinski, J.; Ben-Baruch, N.; Osborne, C.R.; Lardelli, P.; Tercero, J.C.; Holmes, F.A.; Delaloge, S. A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC). J. Clin. Oncol., 2010, 28(15, suppl), 1038.
115. Tedesco, K.L.; Blum, J.L.; Goncalves, A.; Lubinski, J.; Osborne, C.R.C.; Lardelli, P.; Tercero, J.C.; Flores, A.; Holmes, F.A.; Delaloge, S. Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J. Clin. Oncol., 2011, 29 (15, suppl), 1125.
116. Michaelson, D.; Bellmunt, J.; Lewis, N.; Goel, S.; Lee, R.J.; Kaufman, D.S.; Lebedinsky, C.; Nieto, A.; Bayever, E.; Smith, M.R. Phase II study of trabectedin in men with castration resistant prostate cancer (CRPC). 2009 Genitourinary Cancers Symposium, General Poster Session C: Prostate Cancer, Abstract No 175.
117. Michaelson, M.D.; Bellmunt, J.; Hudes, G.R.; Goel, S.; Lee, R.J.; Kantoff, P.W.; Stein, C.A.; Lardelli, P.; Pardos, I.; Kahatt, C.; Nieto, A.; Cullell-Young, M.; Lewis, N.L.; Smith, M.R. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann. Oncol., 2012, 23(5):1234-1240.
118. Massuti, B.; Cobo, M.; Camps, C.; Dómine, M.; Provencio, M.; Alberola, V.; Viñolas, N.; Rosell, R.; Tarón, M.; Gutiérrez-Calderón, V.; Lardelli, P.; Alfaro, V.; Nieto, A.; Isla, D. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer, 2012, 76(3), 354-361.
119. Stoyianni, A.; Kapodistrias, N.; Kampletsas, E.; Pentheroudakis, G.; Pavlidis, N. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori, 2011, 97(2), 252-255.
120. Cioffi, A.; Le Cesne, A.; Blay, J.; Delaloge, S.; Yovine, A.; Maki, R.; Nieto, A.; Jiao, J.J.; Demetri, G.D. Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J. Clin. Oncol., 2009, 27(15, suppl.), e13510.
121. Le Cesne, A.; Yovine, A.; Blay, J.Y.; Delaloge, S.; Maki, R.G.; Misset, J.L.; Frontelo, P.; Nieto, A.; Jiao, J.J.; Demetri, G.D. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest. New Drugs, 2012, 30(3), 1193-1202.
122. Towle, M.J.; Salvato, K.A.; Budrow, J.; Wels, B.F.; Kuznetsov, G.; Aalfs, K.K.; Welsh, S.; Zheng, W.; Seletsky, B.M.; Palme, M.H.; Habgood, G.J.; Singer, L.A.; Dipietro, L.V.; Wang, Y.; Chen, J.J.; Quincy, D.A.; Davis, A.; Yoshimatsu, K.; Kishi, Y.; Yu, M.J.; Littlefield, B.A. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res., 2001, 61(3), 1013-1021.
123. Yu, M.J.; Kishi, Y.; Littlefield, B.A. In: Anticancer agents from natural products; Newman, D.J.; Kingston, D.G.I.; Cragg, G.M., Eds.; Taylor & Francis: Washington, DC, 2005: pp. 241-265.
124. Hirata, Y.; Uemura, D. Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl. Chem., 1986, 58(5), 701-710.
125. Bai, R.L.; Paull, K.D.; Herald, C.L.; Malspeis, L.; Pettit, G.R.; Hamel, E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem., 1991, 266(24), 15882-15889.
126. Jordan, M.A.; Kamath, K.; Manna, T.; Okouneva, T.; Miller, H.P.; Davis, C.; Littlefield, B.A.; Wilson, L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther., 2005, 4, 1086-1095.
127. Okouneva, T.; Azarenko, O.; Wilson, L.; Littlefield, B.A.; Jordan, M.A. Inhibition of Centromere Dynamics by Eribulin mesylate (E7389) during Mitotic Metaphase. Mol. Cancer Ther., 2008, 7(7), 2003-2011.
128. Smith, J.A.; Wilson, L.; Azarenko, O.; Zhu, X.; Lewis, B.M.; Littlefield, B.A.; Jordan, M.A. Eribulin mesylate Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability. Biochemistry, 2010, 49(6), 1331-1337.
129. Kuznetsov, G.; Towle, M.J.; Cheng, H.; Kawamura, T.; TenDyke, K.; Liu, D.; Kishi, Y.; Yu, M.J.; Littlefield, B.A. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analogue E7389. Cancer Res., 2004, 64(16), 5760-5766.
130. Towle, M.J.; Salvato, K.A.; Wels, B.F.; Aalfs, K.K.; Zheng, W.; Seletsky, B.M.; Zhu, X.; Lewis, B.M.; Kishi, Y.; Yu, M.J.; Littlefield, B.A. Eribulin mesylate induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res., 2011, 71(2), 496-505.
131. National Cancer Institute. Cancer Drug Information. Halaven. http://www.cancer.gov/cancertopics/druginfo/fda-eribulinmesylate (Accessed April 13, 2012).
132. Cortes, J.; Lorca, R. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer. Future Oncol., 2011, 7(3), 355-364.
133. National Institute for Health and Clinical Excellence. Halaven. http://publications.nice.org.uk/eribulin-for-the-treatment-of-locally-advanced-or-metastatic-breast-cancer-ta250 (Accessed April 13, 2012).
134. Eisai Website. Research and Development. Major R&D Pipeline. Major R&D Pipeline (Consolidated Financial Report For the Third quarter Fiscal 2011 Reference Data-Released: February 2, 2012). http://www.eisai.com/pdf/eir/erepo/epipeline.pdf (Accessed April 13, 2012).
135. Narayan, S.; Carlson, E.M.; Cheng, H.; Condon, K.; Du, H.; Eckley, S.; Hu, Y.; Jiang, Y.; Kumar, V.; Lewis, B.M.; Saxton, P.; Schuck, E.; Seletsky, B.M.; Tendyke, K.; Zhang, H.; Zheng, W.; Littlefield, B.A.; Towle, M.J.; Yu, M.J. Novel second generation analogues of eribulin mesylate. Part II: Orally available and active against resistant tumors in vivo. Bioorg. Med. Chem. Lett., 2011, 21(6), 1634-1638.
136. Synold, T.W.; Morgan, R.J.; Newman, E.M.; Lenz, H.J.; Gandara, D.R.; Colevas, A.D, Lewis, M.D.; Doroshow, J.H. A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. J. Clin. Oncol., 2005, 23(16S), Part I of II (June 1 Supplement), 3036.
137. Goel, S.; Mita, A.C.; Mita, M.; Rowinsky, E.K.; Chu, Q.S.; Wong N.; Desjardins, C.; Fang, F.; Jansen, M.; Shuster, D.E.; Mani, S.; Takimoto, C.H. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin. Cancer Res., 2009, 15(12), 4207-4212.
138. Tan, A.R.; Rubin, E.H.; Walton, D.C.; Shuster, D.E.; Wong, Y.N.; Fang, F.; Ashworth, S.; Rosen, L.S. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin. Cancer Res., 2009, 15(12), 4213-4219.
139. Mukohara, T.; Nagai, S.; Mukai, H.; Namiki, M.; Minami, H. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest. New Drugs, 2012, 30(5), 1926-1933.
140. Edeline, J.; Lena, H.; Cvitkovic, E.C.; Penel, N.; Reyderman, L.; Edwards, G.; Law, K.; Delord, J.P.D.; Lesimple, T.L. An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate in Patients With Advanced Solid Tumors. Eur. J. Cancer, 2011, 47(Suppl. 1), S158.
141. Dubbelman, A.C.; Rosing, H.; Jansen, R.S.; Mergui-Roelvink, M.; Huitema, A.D.; Koetz, B.; Lymboura, M.; Reyderman, L.; Lopez-Anaya, A.; Schellens, J.H.; Beijnen, J.H. Mass Balance Study of Eribulin mesylate in Patients with Advanced Solid Tumors. Drug Metab. Dispos., 2012, 40(2), 313-321.
142. Swami, U; Petrylak D.P.; Raftopoulos, H.; Shuster, D.E.; Wang, G.; Kumar, V.; Martinez, G.; Goel, S.; Aisner, J. Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol., 2010, 28(15s), 2589.
143. Goel, R.; Chen, E.; Welch, S.; Laurie, S.; Siu, L.; Jonker, D.; Srinivasan, R.; Wang, L.; Ivy, P.; Oza, A. Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J. Clin. Oncol., 2009, 27(suppl; abstr e13509).
144. Gourmelon, C.; Frenel, J.S.; Campone, M. Eribulin mesylate for the treatment of late-stage breast cancer. Expert Opin. Pharmacother., 2011, 12(18), 2883-2890.
145. Jain, S.; Cigler, T. Eribulin mesylate in the treatment of metastatic breast cancer. Biologics, 2012, 6, 21-29.
146. Blum, J.L.; Pruitt, B.T.; Fabian, C.J.; Shuster, D.E.; Meneses, N.L.; Chandrawansa, K.; Fang, F.; Vahdat, L. Phase II study of eribulin mesylate (E7389) in patients with heavily pretreated advanced breast cancer. J. Clin. Oncol., 2007, 25(18S), 1034.
147. Vahdat, L.T.; Pruitt, B.; Fabian, C.J.; Rivera, R.R.; Smith, D.A.; Tan-Chiu, E.; Wright, J.; Tan, A.R.; Dacosta, N.A.; Chuang, E.; Smith, J.; O'Shaughnessy, J.; Shuster, D.E.; Meneses, N.L.; Chandrawansa, K.; Fang, F.; Cole, P.E.; Ashworth, S.; Blum, J.L. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2009, 27(18), 2954-2961.
148. Vahdat, L.T.; Twelves, C.; Allison, M.K.; Cortes, J.A.; Campone, M.; Shuster, D.E.; Wanders, J.; Fang, F.; Gurnani, R.D.; Blum, J.L. Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. J. Clin. Oncol., 2008, 26(15s), 1084.
149. Cortes, J.; Vahdat, L.; Blum, J.L.; Twelves, C.; Campone, M.; Roché, H.; Bachelot, T.; Awada, A.; Paridaens, R.; Goncalves, A.; Shuster, D.E.; Wanders, J.; Fang, F.; Gurnani, R.; Richmond, E.; Cole, P.E.; Ashworth, S.; Allison, M.A. Phase II study of the halichondrin B analogue eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol., 2010, 28(25), 3922-3928.
150. Iwata, H; Aogi, K. Masuda, N.; Mukai, H.; Yoshida, M.; Rai, Y.; Taguchi, K.; Sasaki, Y.; Takashima, S. Efficacy and safety of eribulin mesylate in Japanese patients (pts) with advanced breast cancer. J. Clin. Oncol., 2010, 28(15s), 1081.
151. Aogi, K.; Iwata, H.; Masuda, N.; Mukai, H.; Yoshida, M.; Rai, Y.; Taguchi, K.; Sasaki, Y.; Takashima, S. A phase II study of eribulin mesylate in Japanese patients with heavily pretreated metastatic breast cancer. Ann. Oncol., 2012, 23(6): 1441-1448.
152. Twelves, C.; Cortes, J.; Vahdat, L.T.; Wanders, J.; Akerele, C.; Kaufman, P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer, 2010, 10(2), 160-163.
153. Twelves, C.; Loesch, D.; Blum, J.L.; Vahdat, L.T.; Petrakova, K.; Chollet, P.J.; Akerele, C.E.; Seegobin, S.; Wanders, J.; Cortes, J. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol., 2010, 28(18s), 958.
154. Cortes, J.; O'Shaughnessy, J.; Loesch, D.; Blum, J.L.; Vahdat, L.T.; Petrakova, K.; Chollet, P.; Manikas, A.; Diéras, V.; Delozier, T.; Vladimirov, V.; Cardoso, F.; Koh, H.; Bougnoux, P.; Dutcus, C.E.; Seegobin, S.; Mir, D.; Meneses, N.; Wanders, J.; Twelves, C. Eribulin mesylate monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389). Lancet, 2011, 377(9769), 914-923.
155. Das, A.; Spira, A.; Iannotti, N.; Savin, M.; Zang, E.; Datta, K.; Shapiro, G.; Patturajan, M.; Silberman, S. A phase II study of a novel anti-tubulin, E7389, in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2006, 24(18S), 7106.
156. Gitlitz, B.J.; Tsao-Wei, D.D.; Groshen, S.; Davies, A.; Koczywas, M.; Belani, C.P.; Argiris, A.; Ramalingam, S.; Vokes, E.E.; Edelman, M.; Hoffman, P.; Ballas, M.S.; Liu, S.V.; Gandara, D.R. A Phase II Study of Halichondrin B Analogue Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial. J. Thorac. Oncol., 2012, 7(3), 574-578.
157. Spira, A.I.; Iannotti, N.O.; Savin, M.A.; Neubauer, M.; Gabrail, N.Y.; Yanagihara, R.H.; Zang, E.A.; Cole, P.E.; Shuster, D.; Das, A. A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non-Small-Cell Lung Cancer. Clin. Lung Cancer, 2012, 13(1), 31-38.
158. Schöffski, P.; Hartmann, J.T.; Hohenberger, P.; Krarup-Hansen, A.; Wanders, J.; Hayward, C.; Druyts, D.; Van Glabbeke, M.; Sciot, R.; Blay, J.Y. Eribulin mesylate (E7389) in patients with leiomyosarcoma (LMS) and other (OTH) subtypes of soft tissue sarcoma (STS): a Phase II study from the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC 62052). Eur. J. Cancer Suppl., 2009, 7(2), 591.
159. Schöffski, P.; Ray-Coquard, I.L.; Cioffi, A.; Bui, N.B.; Bauer, S.; Hartmann, J.T.; Krarup-Hansen, A.; Grünwald, V.; Sciot, R.; Dumez, H.; Blay, J.Y.; Le Cesne, A.; Wanders, J.; Hayward, C.; Marreaud, S.; Ouali M.; Hohenberger, P. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. http://www.ncbi.nlm.nih. gov/pubmed?term=%22European Organisation for Research and Treatment of Cancer %28EORTC%29 Soft Tissue and Bone Sarcoma Group %28STBSG%29%22%5BCorporate Author%5D. Lancet Oncol., 2011, 12(11), 1045-1052.
160. Quinn, D.I.; Aparicio, A.M.; Tsao-Wei, D.D.; Groshen, S; Synold, T.; Stadler, W.M.; Massopust, K.; Gandara, D.; Lara, P.N.; Newman, E. Phase II study of eribulin mesylate (Halichondrin B analogue, E7389) in patients with advanced urothelial cancer (AUC). Eur. J. Cancer Suppl., 2009, 7(2), 442.
161. Hensley, M.L.; Kravetz, S.; Jia, X.; Iasonos, A.; Tew, W.; Pereira, L.; Sabbatini, P.; Whalen, C.; Aghajanian, C.A.; Zarwan, C.; Berlin, S. Eribulin mesylate (halichondrin B analogue E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. Cancer, 2012, 118(9), 2403-2410.
162. de Bono, J.S.; Molife, L.R.; Sonpavde, G.; Maroto, J.P.; Calvo, E.; Cartwright, T.H.; Loesch, D.M.; Feit, K.; Das, A.; Zang, E.A.; Wanders, J.; Agoulnik, S.; Petrylak, D.P. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann. Oncol., 2012, 23(5): 1241-1249.
163. Arnold, S.M.; Moon, J.; Williamson, S.K.; Atkins, J.N.; Ou, S.H.; Le Blanc, M.; Urba, S.G. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest. New Drugs, 2011, 29(2), 352-359.
164. Renouf, D.J.; Tang, P.A.; Major, P.; Krzyzanowska, M.K.; Dhesy-Thind, B.; Goffin, J.R.; Hedley, D.; Wang, L.; Doyle, L.; Moore, M.J. A phase II study of the halichondrin B analogue eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest. New Drugs, 2012, 30(3), 1203-1207.
165. Springer. Adis. Brentuximab Vedotin. Drugs in R & D (Open Access), 2011, 11(1), 85-95. http://adisonline.com/drugsrd/Fulltext/2011/11010/Brentuximab_Vedotin.8.aspx (Accessed April 16, 2012).
166. Bartlett, N.; Forero-Torres, A; Rosenblatt, J.; Fanale, M.; Horning, S.J.; Thompson, S.; Sievers, E.L.; Kennedy, D.A. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J. Clin. Oncol., 2009, 27(15s), 8500.
167. FDA. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268781.htm (Accessed April 16, 2012)
168. Bartlett, N.; Grove, L.E.; Kennedy, D.A.; Sievers, E.L.; Forero-Torres, A. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. J. Clin. Oncol., 2010, 28(15s), 8062.
169. Younes, A.; Forero-Torres, A; Bartlett, N.L.; Leonard, J.P.; Rege, B.; Kennedy, D.A; Lorenz, J.M.; Sievers, E.L. Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. J. Clin. Oncol., 2008, 26(May 20 suppl; abstr 8526).
170. Younes, A; Bartlett, N.L.; Leonard, J.P.; Kennedy, D.A.; Lynch, CM.; Sievers, E.L.; Forero-Torres, A. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. New Engl. J. Med., 2010, 363, 1812-1821.
171. Chen, R.W.; Gopal, A.K.; Smith, S.E.; Ansell, S.M.; Rosenblatt, J.D.; Savage, K.J.; Connors, J.M., Engert, A.; Larsen, E.K.; Kennedy, D.A.; Sievers, E.L.; Younes, A. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J. Clin. Oncol, 2011, 29(15s), 8031.
172. Pro, B.; Advani, R.; Brice, P.; Bartlett, N.; Rosenblatt, J.D.; Illidge, T.; Matous, J.; Ramchandren, R.; Fanale, M.A.; Connors, J.M.; Yang, Y.; Sievers, E.L.; Kennedy, D.A.; Shustov, A.R. Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J. Clin. Oncol, 2011, 29(15s), 8032.
173. Hayashi, Y.; Nicholson, B.; Tanaka, K.; Oda, A.; Lloyd, G.K.; Akamatsu, M.; Palladino, M.A.; Kiso, Y. Effect of the phenyl ring modification on the antitumor activity of anti-microtubule agent dehydrophenylahistin. Pept. Sci. 2004, (41th Japanese Peptide Symposium), 2005, 405-406.
174. Kanoh, K.; Kohno, S.; Asari, T.; Harada, T.; Katada, J.; Muramatsu, M.; Kawashima, H.; Sekiya, H.; Uno, I. (-)-Phenylahistin: a new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorg. Med. Chem. Lett., 1997, 7(22), 2847-2852.
175. Fukumoto, K.; Asari, T.; Harada, T.; Kono, S.; Kano, K.; Kawashima, H.; Sekiya, H.; Oomizo, K. Antitumor NSCL-96F037 manufacture with Aspergillus. Chemical Abstracts, 1999, 129(53444) Abstract for JP 10130266, May 19, 1998.
176. Fenical, W.; Jensen, P.R.; Cheng, X.C. Halimide, a cytotoxic marine natural product, and derivatives thereof. U.S. Patent 6,069,146, May 30, 2000.
177. Nicholson, B.; Lloyd G.K.; Miller, B.R.; Palladino, M.A.; Kiso, Y.; Hayashi, Y.; Neuteboom, S.T. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anti-cancer Drugs, 2006, 17(1), 25-31.
178. Yamazaki, Y.; Sumikura, M.; Hidaka, K.; Yasui, H.; Kiso, Y.; Yakushiji, F.; Hayashi, Y. Anti-microtubule 'plinabulin' chemical probe KPU-244-B3 labeled both a-and p-tubulin. Bioorg. Med. Chem., 2010, 18(9), 3169-3174.
179. Yamazaki, Y.; Kido, Y.; Hidaka, K.; Yasui, H.; Kiso, Y.; Yakushiji, F.; Hayashi, Y. Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole. Bioorg. Med. Chem., 2011, 19(1), 595-602.
180. Singh, A.V.; Bandi, M.; Raje, N.; Richardson, P.; Palladino M.A.; Chauhan, D.; Anderson, K.C. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood, 2011, 117(21), 5692-700.
181. Shen, Y.; Liu, C; Bertelsen, L.B.; Nielsen, T.; Horsman, M. R.; Stoedkilde-joerrgensen, H. NPI-2358 rapidly inhibit blood flow in tumor treatment by analyzing dynamic contrast enhanced magnetic resonance imaging parameters. Zhonghua Zhongliu Fangzhi Zazhi (Chinese Journal of Cancer Prevention and Treatment), 2010, 17(7), 488-490.
182. Millward, M.; Mita, A; Spear, M.A.; Federico, K.C; Lloyd, G.K.; Cropp, G.; Mita, M.; Mainwaring, P. Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel. J. Clin. Oncol, 2009, 27(15s), 3571.
183. Nereus Pharmaceuticals Website. Products candidates. A Novel Tumor Vascular Disrupting Agent. http://www.nereuspharm.com/NPI-2358.shtml (Accessed April 16, 2012)
184. Spear, M.A.; LoRusso, P; Tolcher, A.W.; Lin, C; Wang, D.; Heath, E.; Lloyd, G.K.; Cropp, G.; Papadopoulos, K.P. A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358. J. Clin. Oncol, 2007, 25(18s), 14097.
185. LoRusso, P.; Papadopoulos, K.; Tolcher, A.; Lin, C.C.; Lloyd, K.; Morgan, E.; Ashton, E.; Cropp, G.; Spear, M. A Phase 1 accelerated titration dose escalation study of tiie vascular disrupting agent NPI-2358 utilizing DCE-MRI. Angiogenesis Inhibitors: Poster Presentations. Abstract 3987. 98th AACR Annual Meeting, Apr 14-18, 2007. In: http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2007/l_Annual_Meeting/3987?maxtoshow=&hits=10&RESULTFORMAT=&authorl=LoRusso%2C+P&fulltext=npi-2358&andorexactfulltext=and&searchid=l &FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT (Accessed April 17, 2012).
186. Mita, A.C.; Yee, L.K.; Papadopoulos, K.P.; Heath, E.I.; Romero, O.; Lloyd, G.K.; Cropp, G.; Spear, M.A.; Mita, M.M.; LoRusso, P.M. Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. J. Clin. Oncol, 2008, 26(15s), 3525.
187. Mita, M.M.; Spear, M.A.; Yee, L.K.; Mita, A.C.; Heath, E.I.; Papadopoulos, K.P.; Federico, K.C.; Reich, S.D.; Romero, O.; Malburg L.; Pilat, M.; Lloyd, G.K.; Neuteboom, S.T.; Cropp, G.; Ashton, E.; LoRusso, P.M. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin. Cancer Res., 2010, 16(23), 5892-5899.
188. Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G.K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M.A. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest. New Drugs, 2012, 30(3), 1065-1073.
189. Ferrer, E.; Bolos, J.; Castaner, R. Plinabulin: tubulin polymerization inhibitor vascular-disrupting agent oncolytic. Drugs Future, 2010, 35(1), 11-15.
190. Nereus Pharmaceuticals Website. Products candidates. Clinical trials for Plinabulin (NPI-2358)(VDA). http://www.nereuspharm.com/ClinicalTrialsNPI-2358.shtml (Accessed April 17, 2012).
191. Mita, A.C.; Heist, R.S.; Aren, O.; Mainwaring, P.N.; Bazhenova, L.; Gadgeel, S.M.; Blum, R.H.; Polikoff, J.; Biswas, J.; Spear, M.A. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2010, 28(15s), 7592.
192. Heist, R.; Aren, O.; Millward, M.; Mainwaring, P.; Mita, A.; Mita, M.; Bazhenova, L.; Blum, R.; Polikoff, J.; Gadgeel, S.; Deshmukh, C; Llyod, G.K.; Reich, S.; Spear, M.A. Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI-2358) combined with docetaxel in patients with non-small cell lung cancer (NSCLC). Mol. Cancer Ther., 2009, 8(12s), C30.
193. th Japanese Peptide Symposium, 315-316.
194. Hayashi, Y.; Yamazaki, Y.; Sumikura, M.; Yoshida, T.; Mori, Y.; Yasui, H.; Kohno, K.; Kiso, Y.; Neuteboom, S.; Potts, B.; Lloyd, K.G. Plinabulin a diketopiperazine-type vascular targeting anti-cancer agent based on microtubule depolymerization activity. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 (2010), MEDI-279.
195. Yamazaki, Y.; Tanaka, K.; Nicholson, B.; Deyanat-Yazdi, G.; Potts, B.; Yoshida, T.; Oda, A.; Kitagawa, T.; Orikasa, S.; Kiso, Y.; Yasui, H.; Akamatsu, M.; Chinen, T.; Usui, T.; Shinozaki, Y.; Yakushiji, F.; Miller, B. R; Neuteboom, S.; Palladino, M.; Kanoh, K.; Lloyd, G. K.; Hayashi, Y. Synthesis and Structure-Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure. J. Med. Chem., 2012, 55(3), 1056-1071.
196. Chun, H.G.; Davies, B.; Hoth, D.; Suffness, M.; Plowman, J.; Flora, K.; Grieshaber, C; Leyland-Jones, B. Didemnin B, the first marine compound entering clinical trials as an antineoplastic agent. Invest. New Drugs, 1986, 4(3), 279-284.
197. García-Fernández, L.F.; Losada, A.; Alcaide, V.; Alvarez, A.M.; Cuadrado, A.; González, L.; Nakayama, K.; Nakayama, K.I.; Fernández-Sousa, J.M.; Mufloz, A.; Sánchez-Puelles, J.M. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene, 2002, 21(49), 7533-7544.
198. Cuadrado, A.; Garcia-Fernandez, L.F.; Gonzalez, L.; Suarez, Y.; Losada, A.; Alcaide, V.; Martinez, T.; Fernandez-Sousa, J.M.; Sanchez-Puelles, J.M.; Munoz, A. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J. Biol. Chem., 2003, 278(1), 241-250
199. Broggini, M.; Marchini, S.V.; Galliera, E.; Borsotti, P.; Taraboletti, G.; Erba, E.; Sironi, M.; Jimeno, J.; Faircloth, G.T.; Giavazzi, R.; D'Incalci, M. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17(1), 52-59.
200. Schwartsmann, G.; Da Rocha, A.B.; Mattei, J.; Lopes, R. Marine-derived anticancer agents in clinical trials. Expert Opin. Investig. Drugs, 2003, 12(8), 1367-1383.
201. Faivre, S.; Chièze, S.; Delbaldo, C.; Ady-Vago, N.; Guzman, C.; Lopez-Lazaro, L.; Lozahic, S.; Jimeno, J.; Pico, F.; Armand, J.P.; Martin, J.A.; Raymond, E. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J. Clin. Oncol., 2005, 23(31), 7871-7880.
202. Geoerger, B.; Doz, F.; Lowis, S.; Kearns, K.; Estlin, E.; Gibson, B.; Corradini, N.; Lardelli, P.; Vassal, G. Phase I-II clinical and pharmacokinetic study of plitidepsin in children with malignant tumors. J. Clin. Oncol., 2008, 26(15s), 10028.
203. Maroun, J.A.; Belanger, K.; Seymour, L.; Matthews, S.; Roach, J.; Dionne, J.; Soulieres, D.; Stewart, D.; Goel, R.; Charpentier, D.; Goss, G.; Tomiak, E.; Yau, J.; Jimeno, J.; Chiritescu, G. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. Ann. Oncol., 2006, 17(9), 1371-1378.
204. Izquierdo, M.A.; Bowman, A.; García, M.; Jodrell, D.; Martinez, M.; Pardo, B.; Gómez, J.; López-Martin, J.A.; Jimeno, J.; Germá, J.R.; Smyth, J.F. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res., 2008, 14(10), 3105-3112.
205. Schöffski, P.; Guillem, V.; Garcia, M.; Rivera, F.; Tabernero, J.; Cullell, M.; Lopez-Martin, J.A.; Pollard, P.; Dumez, H.; del Muro, X.G.; Paz-Ares, L. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar. Drugs, 2009, 7(1), 57-70.
206. Eisen, T.; Thomas, J.; Miller Jr., W.H.; Gore, M.; Wolter, P.; Kavan, P.; Martín, J.A.; Lardelli, P. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res., 2009, 19(3), 185-192.
207. Baudin, E.; Droz, J.P.; Paz-Ares, L.; van Oosterom, A.T.; Cullell-Young, M.; Schlumberger, M. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am. J. Clin. Oncol., 2010, 33(1), 83-88.
208. Le Tourneau, C.; Faivre, S.; Ciruelos, E.; Domínguez, M.J.; López-Martín, J.A.; Izquierdo, M.A.; Jimeno, J.; Raymond, E. Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. Am. J. Clin. Oncol., 2010, 33(2), 132-136.
209. Mateos, M.V.; Cibeira, M.T.; Richardson, P.G.; Prosper, F.; Oriol, A.; de la Rubia, J.; Lahuerta, J.J.; García-Sanz, R.; Extremera, S.; Szyldergemajn, S.; Corrado, C.; Singer, H.; Mitsiades, C.S.; Anderson, K.C.; Bladé, J.; San Miguel; J. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. J. Clin. Cancer Res., 2010, 16(12), 3260-3269.
210. Geoergera, B.; Estlinb, E.J.; Aertsc, I.; Kearnsd, P.; Gibsone, B.; Corradinif, N.; Dozc, F.; Lardellih, P.; de Miguelh, B.; Sotoh, A.; Pradosh, R.; Vassala, G. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumors: An Innovative Therapies for Children with Cancer (ITCC) study. Eur. J. Cancer, 2012, 48(3), 289-296.
211. Peschel, C.; Hartmann, J.T.; Schmittel, A.; Bokemeyer, C.; Schneller, F; Keilholz, I.; Buchheidt, D.; Millan, S.; Izquierdof, M.A.; Hofheinze, R.D. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer, 2008, 60(3), 374-380.
212. Eisen, T.; Thatcher, N.; Leyvraz, S.; Miller Jr., W.H.; Couture, F.; Lorigan, P.; Lüthi, F.; Small, D.; Tanovic, A.; O'Brien, M. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer, 2009, 64(1), 60-65.
213. ClinicalTrials.Gov Website. Plitidepsin. NCT00229203 Study Results. http://clinicaltrials.gov/ct2/show/results/NCT00229203? term=plitidepsin&rank=6 (Accessed May 05, 2012).
214. Hummer, R.; Hayward, L.; Lorigan, P.; Soriano, V.; Moiseyenko, V.; Szyldergemajn, S.; Prados, R.; Smyth, J.; Calvert, H. Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). J. Clin. Oncol, 2009, 27(15s), 9059.
215. Oaknin, A.; Plummer, R.; Salazar, R.; Robinson, A.; Pardo, B.; Razak, A.A.; Cuadra, C; Flores, L.; Izquierdo, M.A.; Calvert, H. Phase I combination study of plitidepsin and carboplatin in advanced solid tumors. J. Clin. Oncol, 2007, 25(18s), 2558.
216. Salazar, R.; Plummer, R.; Oaknin, A.; Robinson, A.; Pardo, B.; Soto-Matos, A.; Yovine, A.; Szyldergemajn, S.; Calvert, A.H. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. Invest. New Drugs, 2011, 29(6), 1406-1413.
217. Gomez-Roca, C; Besse-Hammer, T.; Szyldergemajn, S.; Bahleda, R.; Diaz, M.; Vandermeeren, A.; Extremera, S.; Kahatt, C; Soria, J.C.; Awada, A. Phase lb study of plitidepsin with bevacizumab in refractory solid tumor patients. Eur. J. Cancer Suppl, 2010, 8(7), 137.
218. Hamann, M.T.; Otto, C.S.; Scheuer, P.J.; Dunbar, D.C. Kahalalides: bioactive peptides from a marine mollusc Elysia rufescens and its diet algal Bryopsis sp. J. Org. Chem., 1996, 67(19), 6594-6600.
219. Rademaker-Lakhai, J.M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; de Reijke, T.M.; Jimeno, J.M.; Lopez-Lazaro, L.; Lopez Martin, J.A.; Beijnen, J.H.; Schellens, J.H.M. Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer. Clin. Cancer Res., 2005, 11, 1854-1862.
220. E.U. Clinical Trials Registry. Kahalalide. Clinical and pharmacokinetic phase II study of one hour infusion of kahalalide F administered every week to patients with Non Small Cell Lung Cancer Stage IIIB with pleural effusion and stage IV, after first line chemotherapy. EudraCT Number: 2004-001253-29. https://www.clinicaltrialsregister.eu/ctr-search/search?query=kahalalide (Accessed April 17, 2012).
221. Pharmamar Website. Products. Pipeline. http://www.pharmamar. com/pipeline.aspx (Accessed April 17, 2012).
222. Pharmamar Website. Products. Pipeline. Irvalec. http://www.pharmamar.com/irvalec.aspx (Accessed April 17, 2012).
223. Yi-He Ling, Y.H.; Aracil, M.; Jimeno, J.; Perez-Soler, R.; Zou, Y. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur. J. Cancer, 2009, 45(10), 1855-1864.
224. Váradi, T.; Roszik, J.; Lisboa, D.; Vereb, G.; Molina-Guijarro, J.M.; Galmarini, CM.; Szöllosi, J.; Nagy, P. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur. J. Pharmacol, 2011, 667(1-3), 91-99.
225. Faivre, S.J.; Ropert, S.; Coronado, C; Alcantara, J.; de Miguel, B.; Soto, A.; Szyldergemajn, S.A.; Loussilaho, G.; Mir, O.; Goldwasser, F.; Raymond, E. Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors. J. Clin. Oncol, 2011, 29(15s), el3097.
226. Bruce, J.Y.; Geary, D.; de las Heras, B. Phase I study of PM02734: association of dose-limiting hepatotoxicity with plasma concentrations. J. Clin. Oncol, 2008, 26(15s), 2513.
227. Szyldergemajn, S.A.; Gonçalves, A.; Metges, J.P.; Gunzer, K.; Montagut, C; Salazar, R.; Alsina, M.; Evans, T.R.J.; Swinson, D.; Petty, R.D.; Singer, H.; Kahatt, CM. IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced gastroesophageal cancer. J. Clin. Oncol, 2011, 29(15s), TPS169.
228. Charupant, K.; Daikuhara, N.; Saito, E.; Amnuoypol, S.; Suwanborirux, K.; Owa, T.; Saito, N. Chemistry of renieramycins. Part 8: Synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues. Bioorg. Med. Chem., 2009, 17(13), 4548-4558.
229. Guirouilh-Barbat, J.; Antony, S.; Pommier, Y. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol. Cancer Ther., 2009, 8(7), 2007-2014.
230. Leal, J.F.; García-Hernández, V.; Moneo, V.; Domingo, A.; Bueren-Calabuig, J.A.; Negri, A.; Gago, F.; Guillén-Navarro, M.J.; Avilés, P.; Cuevas, C.; García-Fernández, L.F.; Galmarini, C.M. Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem. Pharmacol., 2009, 78(2), 162-170.
231. Ocio, E.M.; Maiso, P.; Chen, X.; Garayoa, M.; Alvarez-Fernández, S.; San-Segundo, L.; Vilanova, D.; López-Corral, L.; Montero, J.C.; Hernández-Iglesias, T.; de Alava, E.; Galmarini, C.; Avilés, P.; Cuevas, C.; San-Miguel, J.F.; Pandiella, A. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood, 2009, 113(16), 3781-3791.
232. Pérez-Ruixo, C.; Valenzuela, B.; Fernández, T.C.; González-Sales, M.; Miguel-Lillo, B.; Soto-Matos, A.; Pérez-Ruixo, J.J. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients. Cancer Chemother. Pharmacol., 2012, 69(1), 15-24.
233. Soria, J.C.; Plummer, R.; Soto, A.; Massard, C.; Calvert, H.; Prados, R.; Angevin, E.; Jones, C.; de las Heras, B. Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma. Eur. J. Cancer Suppl., 2008, 6(12), 57.
234. Calvo, E.; Gil, M.; Coronado, C.; Valer, A.; Duran, I.; Hidalgo, M.; Pardo, B.; Calles, A.; García, M.; Morelli, P.; Kahatt, C.M.; Prados, R.; Fernandez, C.; Salazar, R. Phase I study of PM00104 in combination with carboplatin (C) in patients (pts) with advanced solid tumors. J. Clin. Oncol., 2011, 29(15s), e13085.
235. Leal, J.F.; Martínez-Díez, M.; García-Hernández, V.; Moneo, V.; Domingo, A.; Bueren-Calabuig, J.A.; Negri, A.; Gago, F.; Guillén-Navarro, M.J.; Avilés, P.; Cuevas, C.; García-Fernández, L.F.; Galmarini, C.M. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumor activity. Brit. J. Pharmacol., 2010, 161(5), 1099-1110.
236. Soares, D.G.; Rocca, C.J.; Machado, M.; Poindessous, V.; Ouaret, D.; Sarasin, A.; Galmarini, C.; Henriques, J.A.P.; Escargueil, A.E.; Larsen, A.K. The marine-derived product PM01183 shows activity toward platinum-resistant cells and attenuates nucleotide excision repair. Eur. J. Cancer Suppl., 2010, 8(7), 166-167.
237. Soares, D.G.; Machado, M.S.; Rocca, C.J.; Poindessous, V.; Ouaret, D.; Sarasin, A.; Galmarini, C.M.; Henriques, J.A.; Escargueil, A.E.; Larsen, A.K. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol. Cancer Ther., 2011, 10(8), 1481-1489.
238. Pharmamar Website. Products. PM01183. http://www.pharmamar. com/pm01183-en.aspx (Accessed April 17, 2012).
239. Ratain, M.J.; Elez, M.E.; Szyldergemajn, S.; Geary, D.; Kang, S.P.; Maraculla, T.; Yovine, A.; Soto-Matos, A.; Tabernero, J. First-in-man phase I study of PM01183 using an accelerated titration design. Eur. J. Cancer Suppl., 2010, 8(7), 137-138.
240. Ray, A.; Okouneva, T.; Manna, T.; Miller, H.P.; Schmid, S.; Arthaud, L.; Luduena, R.; Jordan, M.A.; Wilson, L. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res., 2007, 67(8), 3767-3776.
241. Garg, V.; Zhang, W.; Gidwani, P.; Kim, M.; Kolb, E.A. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin. Cancer Res., 2007, 13(18 Pt 1), 5446-5454.
242. Ebbinghaus, S.; Rubin, E.; Hersh, E.; Cranmer, L.D.; Bonate, P.L.; Fram, R.J.; Jekunen, A.; Weitman, S.; Hammond, L.A. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res., 2005, 11(21), 7807-7816.
243. Cunningham, C.; Appleman, L.J.; Kirvan-Visovatti, M.; Ryan, D.P.; Regan, E.; Vukelja, S.; Bonate, P.L.; Ruvuna, F.; Fram, R.J.; Jekunen, A.; Weitman, S.; Hammond, L.A.; Eder, J.P. Jr. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res., 2005, 11(21), 7825-7833.
244. Mita, A.C.; Hammond, L.A.; Bonate, P.L.; Weiss, G.; McCreery, H.; Syed, S.; Garrison, M.; Chu, Q.S.; DeBono, J.S.; Jones, C.B.; Weitman, S.; Rowinsky, E.K. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin. Cancer Res., 2006, 12(17), 5207-5215.
245. Genzyme Oncology Website. Our research. Tasidotin Hydrochloride. http://www.genzymeoncology.com/onc/research/onc_p_tasidotinHydrochloride.asp (Accessed April 17, 2012).
246. Pettit, G.R.; Kamano, Y.; Fujii, Y.; Herald, C.L.; Inoue, M.; Brown, P.; Gust, D.; Kitahara, K.; Schmidt, J.M.; Doubek, D.L.; Michael, C. Marine animal biosynthetic constituents for cancer chemotherapy. J. Nat. Prod., 1981, 44 (4), 482-485.
247. Kornprobst, J.M. In: Encyclopedia of marine natural products; Wiley-VCH Verlag GmbH & Co, KGaA, Weinheim, Germany, 2010. Vol. 3, pp.1162-1166.
248. Pettit, G.R. The dolastatins. Prog. Chem. Org. Nat. Prod., 1997, 70, 1-79.
249. de Jonge, M.J.; van der Gaast, A.; Planting, A.S.; van Doorn, L.; Lems, A.; Boot, I., Wanders, J.; Satomi, M.; Verweij, J. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin. Cancer Res. 2005, 11(10), 3806-3813.
250. Tamura, K.; Nakagawa, K.; Kurata, T.; Satoh, T.; Nogami, T.; Takeda, K.; Mitsuoka, S.; Yoshimura, N.; Kudoh, S.; Negoro, S.; Fukuoka, M. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother. Pharmacol., 2007, 60(2), 285-293.
251. Patel, S.; Keohan, M.L.; Saif, M.W.; Rushing, D.; Baez, L.; Feit, K.; De Jager, R.; Anderson, S. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer, 2006, 107(12), 2881-2887.
252. Hwu, P.; Sznol, M.; Kluger, H.; Rink, L.; Kim, K.B.; Papadopoulos, N.E.; Sanders, D.; Boasberg, P.; Ooi, C.E.; Hamid, O. A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. J. Clin. Oncol., 2008, 26(May 20 suppl; abstr 9029).
253. Morris, S.; Kantoff, P.W.; Petrylak, D.P.; Pomerantz M.; Rotshteyn, Y.; Olson, W.C.; Israel, R.J. A phase I trial of prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC) in taxane-refractory prostate cancer. Molecular Markers meeting, 2010, abstract n 25.
254. Kantoff, P.; Petrylak, D.P.; Pomerantz, M, Israel R.J.; Olson, W.C.; Ramakrishna, T.; Morris, S. First-in-human phase I trail of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer. J. Clin. Oncol., 2010, 28(15s) (suppl. abstract TPS245).
255. Petrylak, D.P.; Kantoff, P.W.; Franck, R.C.; Shore, N.D.; Rotshteyn, Y.; Israel, R.J.; Olson, W.C.; Ramakrishna, T.; Morris, S. Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): a phase I trial in taxane-refractory prostate cancer. J. Clin. Oncol., 2011, 29(suppl. abstract 4650).
256. Thompson, J.A.; Forero-Torres, A.; Heath, E.I.; Ansell, S. M.; Pal, S. K.; Infante, J. R.; De Vos, S.; Hamlin, P. A.; Zhao, B.; Klussman, K.; Whiting, N. C. The effect of SGN-75, a novel antibody-drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study. J. Clin. Oncol., 2011, 29 (suppl; abstr 3071).
257. Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. Engl., 2003, 42(3), 355-357.
258. Fenical, W.; Jensen, P.R.; Palladino, M.A.; Lam, K.S.; Lloyd, G.K.; Potts, B.C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem., 2009, 17(6), 2175-2180.
259. Reddy, L.R.; Saravanan, P.; Corey, E.J. A simple stereocontrolled synthesis of salinosporamide A. J. Am. Chem. Soc., 2004, 126(20), 6230-6231.
260. Chauhan, D.; Hideshima, T.; Anderson, K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Brit. J. Cancer, 2006, 95(8), 961-965.
261. Shah, J.J.; Orlowski, R.Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia, 2009, 23(11), 1964-1979.
262. Potts, B.C.; Albitar, M.X.; Anderson, K.C.; Baritaki, S.; Berkers, C.; Bonavida, B.; Chandra, J.; Chauhan, D.; Cusak, J.C. Jr.; Fenical, W.; Ghobrial, I.M.; Groll, M.; Jensen, P.R.; Lam, K.S.; Lloyd, G.K.; McBride, W.; McConkey, D.J.; Miller C.P.; Neuteboom, S.T.C.; Oki, Y.; Ovaa, H.; Pajonk, F.; Richardson, P.G.; Roccaro, A.M.; Slossn C.M.; Spear, M.A.; Valashi, E.; Younes, A.; Palladino, M.A. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr. Cancer Drug Targets, 2011, 11(3), 254-284.
263. Nereus Pharmaceuticals Website. Products Candidates. A novel proteasome inhibitor (NPI-0052). http://www.nereuspharm.com/NPI-0052.shtml (Accessed April 17, 2012).
264. Hamlin, P.A.; Aghajanian, C.; Younes, A.; Hong, D.S; Palladino, A; Longenecker, M.; Lloyd, G.K.; Hannah, A.L.; Spear, M.A.; Kurzrock, R. First-in-Human Phase 1 Study of the Novel Structure Proteasome Inhibitor NPI-0052. J. Clin. Oncol., 2009, 27(15s), 3516.
265. Kurzrock, R.; Hamlin, P.; Gordon, M.; Hong, D.; Fu, S.; Younes, A.; Hannah, A.; Palladino, M.A.; Spear, M.A.; Aghajanian, C. NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors. Eur. J. Cancer Suppl., 2008, 6(12), 73-74.
266. Townsend, A.; Padrik, P.; Mainwaring, P.; Price, T.; Catley, L.; Longenecker, A.; Palladino, M.; Lloyd, G.K.; Spear, M.; Millward, M. Phase 1 clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D cohort. Eur. J. Cancer Suppl., 2008, 6(12), 74.
267. Price, T.; Padrik, P.; Townsend, A.; Mainwaring, P.; Catley, L.; Longenecker, A.; Cropp, G.; Palladino, M.; Lloyd, G.K.; Spear, M.; Millward, M. Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL. Blood (ASH Annual Meeting Abstracts), 2008, 112, 4934.
268. Hamlin, P.; Aghajanian, C.; Hong, D.; Younes, A.; Palladino, M.; Longenecker, A.; Cropp, G.; Lloyd, G.K.; Hannah, A.; Spear, M.; Kurzrock, R. First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor. Blood (ASH Annual Meeting Abstracts), 2008, 112, 4939.
269. Kurzrock, R.; Hamlin, P.; Younes, A.; Hong, D.; Gordon, M.; Spear, M.; Palladino, M.; Lloyd, G.K.; Longenecker, A.; Neuteboom, S.; Cropp, G.; Hannah, A.; Aghajanian, C. Phase 1 Clinical Trials of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors. Blood (ASH Annual Meeting Abstracts), 2007, 110, 4504.
270. Kurzrock, R.; Hamlin, P.; Younes, A.; Hong, D.; Gordon, M.; Hannah, A.; Palladino, M.A.; Lloyd, G.K.; Longenecker, A.M.; Neuteboom, S.T.C.; Cropp, G.F.; Spear, M.A.; Aghajanian, C. Results from Phase 1 Dose Escalation Study of the Proteasome Inhibitor NPI 0052 in Patients with Solid Tumors and Lymphomas. In: AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, 2007, San Francisco. Poster Session B, (abstract #B1), 2007, 162.
271. Richardson, P.; Hofmeister, C.; Jakubowiak, A; Zimmerman, T.M.; Spear, M.A.; Palladino, M.A.; Longenecker, A.M.; Kelly, S.L.; Neuteboom, S.; Cropp, G.F.; Lloyd, G.K.; Hannah, A.L.; Anderson, K.C. Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM). 51st annual meeting of the American Society of Hematology (ASH), 2009, Oral Session: Myeloma-Therapy, excluding Transplantation: New Drugs in Multiple Myeloma and Amyloidosis. http://ash.confex.com/ash/2009/webprogram/Paper20184.html (Accessed April 17, 2012).
272. Spencer, A.; Millward, M.; Mainwaring, P.; Harrison, S.; Catley, L.; Townsend, A.; Sukumaran, S.; Longenecker, A.M.; Palladino, M.A.; Lloyd, G.K.; Neuteboom, S.; Padrik, P.; Spear, M.A.; Price, T. Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052. 51st annual meeting of the American Society of Hematology (ASH), 2009. Poster Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster II. http://ash.confex.com/ash/2009/webprogram/Paper20339.html (Accessed April 17, 2012).
273. Richardson, P.; Hofmeister, CC.; Zimmerman, T.M.; Chanan-Khan, A.A.; Spear, M.A.; Palladino, M.A.; Longenecker, A.M.; Cropp, G.; Lloyd, G.K.; Wear, S.; Hannah, A.L.; Anderson, K.C. Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma. 50st annual meeting of the American Society of Hematology (ASH), 2008. Poster Session: Myeloma-Therapy, Excluding Transplantation Poster II. http://ash.confex.com/ash/2008/webprogram/Paper6139.html (Accessed April 17, 2012).
274. Townsend, A.R.; Millward, M.; Price, T.; Mainwaring, P.; Spencer, A.; Longenecker, A.; Palladino, M.A.; Lloyd, G.K.; Spear, M.A.; Padrik, P. Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J. Clin. Oncol., 2009, 27(15s), 3582.
275. Hofmeister, C.C.; Richardson, P.; Zimmerman, T.; Spear, M.A.; Palladino, M.A.; Longenecker, A.M.; Cropp, G.F.; Lloyd, G.K.; Hannah, A.L.; Anderson, K. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM). J. Clin. Oncol., 2009, 27(15s), 8505.
276. Richardson, P.G.; Spencer, A.; Cannell, P.; Harrison, S.J.; Catley, L.; Underhill, C.; Zimmerman, T.M.; Hofmeister, C.C.; Jakubowiak, A.J.; Laubach, J.P.; Palladino, M.A.; Longenecker, A.M.; Lay, A.; Wear, S.; Lloyd, G.K.; Hannah, A.L.; Reich, S.; Spear, M.A.; Anderson, K.C. Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). 53st annual meeting of the American Society of Hematology (ASH), 2011, Session: 653. Myeloma-Therapy, excluding Transplantation: New Agents in Myeloma. http://ash.confex.com/ash/2011/webprogram/Paper37217.html (Accessed April 17, 2012).
277. Price, T.; Millward, M.; Mainwaring, P.; Harrison, S.; Catley, L.; Townsend, A.; Sukumaran, S.; Longenecker, A.; Palladino, M.A.; Lloyd, G.K.; Neuteboom, S.; Padrik, P.; Spear, M.A.; Spencer, A. A two-arm phase 1 clinical trial with NPI-0052, a novel proteasome inhibitor. Mol. Cancer Ther., 2009, 8(12), Supplement 1, C33. doi: 10.1158/1535-7163.TARG-09-C33.
278. Millward, M.; Price, T.; Townsend, A.; Sweeney, C.; Spencer, A.; Sukumaran, S.; Longenecker, A.; Lee, L.; Lay, A.; Sharma, G.; Gemmill, R.M.; Drabkin, H.A.; Lloyd, G.K.; Neuteboom, S.T.; McConkey, D.J.; Palladino, M.A.; Spear, M.A. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drugs, 2011 Nov 12. [Epub ahead of print].
279. Faro de Vigo. Secciones. PharmaMar inicia el ensayo clínico de un nuevo producto contra cánceres sólidos. http://www.farodevigo.es/sociedad-cultura/2011/02/08/pharmamar-inicia-ensayo-clinico-nuevo-producto-canceres-solidos/516484.html (Accessed April 17, 2012).
280. Pharmamar Website. Products. PM060184. http://www.pharmamar.com/pm060184-en.aspx (Accessed April 17, 2012).